Bereich
Rheumatologie
RHEUMA · Dept. I
Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry.
Ciurea A, Götschi A, Bräm R, Bürki K, Exer P, Andor M, Nissen M, Möller B, Hügle T, Rubbert-Roth A, Kyburz D, Distler O, Scherer A, Micheroli R. Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry. RMD Open 2023; 9
01.12.2023Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry.
01.12.2023RMD Open 2023; 9
Ciurea Adrian, Götschi Andrea, Bräm René, Bürki Kristina, Exer Pascale, Andor Michael, Nissen Michael J, Möller Burkhard, Hügle Thomas, Rubbert-Roth Andrea, Kyburz Diego, Distler Oliver, Scherer Almut, Micheroli Raphael
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis.
Rubbert-Roth A, Kakehasi A, Takeuchi T, Schmalzing M, Palac H, Coombs D, Liu J, Anyanwu S, Lippe R, Curtis J. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis. Rheumatol Ther 2023
20.11.2023Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis.
20.11.2023Rheumatol Ther 2023
Rubbert-Roth Andrea, Kakehasi Adriana M, Takeuchi Tsutomu, Schmalzing Marc, Palac Hannah, Coombs Derek, Liu Jianzhong, Anyanwu Samuel I, Lippe Ralph, Curtis Jeffrey R
Worse cardiovascular and renal outcome in male SLE patients.
Mihailovic J, Ribi C, Chizzolini C, Trendelenburg M, von Kempis J, Dahdal S, Huynh-Do U, Swiss Systemic Lupus Erythematosus Cohort Study Group (SSCS). Worse cardiovascular and renal outcome in male SLE patients. Sci Rep 2023; 13:18628.
30.10.2023Worse cardiovascular and renal outcome in male SLE patients.
30.10.2023Sci Rep 2023; 13:18628
Mihailovic Jelena, Ribi Camillo, Chizzolini Carlo, Trendelenburg Marten, von Kempis Johannes, Dahdal Suzan, Huynh-Do Uyen, Swiss Systemic Lupus Erythematosus Cohort Study Group (SSCS)
Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care.
Riek M, Scherer A, Möller B, Ciurea A, Von Mühlenen I, Gabay C, Kyburz D, Brulhart L, von Kempis J, Mueller R, Hasler P, Strahm T, von Känel S, Zufferey P, Dudler J, Finckh A. Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care. Sci Rep 2023; 13:17776.
18.10.2023Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care.
18.10.2023Sci Rep 2023; 13:17776
Riek Myriam, Scherer Almut, Möller Burkhard, Ciurea Adrian, Von Mühlenen Ines, Gabay Cem, Kyburz Diego, Brulhart Laure, von Kempis Johannes, Mueller Ruediger B, Hasler Paul, Strahm Tanja, von Känel Sabine, Zufferey Pascal, Dudler Jean, Finckh Axel
Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.
Spiera R, Unizony S, Warrington K, Sloane J, Giannelou A, Nivens M, Akinlade B, Wong W, Bhore R, Lin Y, Buttgereit F, Devauchelle-Pensec V, Rubbert-Roth A, Yancopoulos G, Marrache F, Patel N, Dasgupta B, SAPHYR Investigators. Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper. N Engl J Med 2023; 389:1263-1272.
05.10.2023Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.
05.10.2023N Engl J Med 2023; 389:1263-1272
Spiera Robert F, Unizony Sebastian, Warrington Kenneth J, Sloane Jennifer, Giannelou Angeliki, Nivens Michael C, Akinlade Bolanle, Wong Wanling, Bhore Rafia, Lin Yong, Buttgereit Frank, Devauchelle-Pensec Valérie, Rubbert-Roth Andrea, Yancopoulos George D, Marrache Frederic, Patel Naimish, Dasgupta Bhaskar, SAPHYR Investigators
TENDINOPATHIEN – eine allgemeininternistische, rheumatologische und sportmedizinische Herausforderung.
Haller C, Noack P, Neumann T. TENDINOPATHIEN – eine allgemeininternistische, rheumatologische und sportmedizinische Herausforderung. - Wie wirksam sind Eigenblut (PRP) Injektionen und wo kann Stosswellentherapie (ESWT) evidenz-basiert angeboten werden?. Der Informierte Arzt 2023; Oktober 2023:29-32.
01.10.2023TENDINOPATHIEN – eine allgemeininternistische, rheumatologische und sportmedizinische Herausforderung.
01.10.2023Der Informierte Arzt 2023; Oktober 2023:29-32
Haller Christoph, Noack Patrik, Neumann Thomas
Cluster Analysis to Explore Clinical Subphenotypes of Eosinophilic Granulomatosis With Polyangiitis.
Rubenstein E, Maldini C, Vaglio A, Bello F, Bremer J, Moosig F, Bottero P, Pesci A, Sinico R, Grosskreutz J, Feder C, Saadoun D, Trivioli G, Maritati F, Rewerska B, Szczeklik W, Fraticelli P, Guida G, Gregorini G, Moroncini G, Hellmich B, Zwerina J, Resche-Rigon M, Emmi G, Neumann T, Mahr A. Cluster Analysis to Explore Clinical Subphenotypes of Eosinophilic Granulomatosis With Polyangiitis. J Rheumatol 2023; 50:1446-1453.
22.09.2023Cluster Analysis to Explore Clinical Subphenotypes of Eosinophilic Granulomatosis With Polyangiitis.
22.09.2023J Rheumatol 2023; 50:1446-1453
Rubenstein Emma, Maldini Carla Soledad, Vaglio Augusto, Bello Federica, Bremer Jan Phillip, Moosig Frank, Bottero Paolo, Pesci Alberto, Sinico Renato Alberto, Grosskreutz Julian, Feder Claudia, Saadoun David, Trivioli Giorgio, Maritati Federica, Rewerska Barbara, Szczeklik Wojciech, Fraticelli Paolo, Guida Giuseppe, Gregorini Gina, Moroncini Gianluca, Hellmich Bernhard, Zwerina Jochen, Resche-Rigon Matthieu, Emmi Giacomo, Neumann Thomas, Mahr Alfred
Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases.
Finckh A, Ciurea A, Raptis C, Rubbert-Roth A. Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases. J Infect Dis 2023; 228:S13-S23.
04.08.2023Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases.
04.08.2023J Infect Dis 2023; 228:S13-S23
Finckh Axel, Ciurea Adrian, Raptis Catherine E, Rubbert-Roth Andrea
Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis.
Alamo B, Moi L, Bajema I, Faurschou M, Flossmann O, Hauser T, Hruskova Z, Jayne D, Luqmani R, Mahr A, Åkesson A, Westman K, EUVAS. Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2023; 38:1655-1665.
30.06.2023Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis.
30.06.2023Nephrol Dial Transplant 2023; 38:1655-1665
Alamo Beatriz Sanchez, Moi Laura, Bajema Ingeborg M, Faurschou Mikkel, Flossmann Oliver, Hauser Thomas, Hruskova Zdenka, Jayne David R.W., Luqmani Raashid A, Mahr Alfred, Åkesson Anna, Westman Kerstin, EUVAS
Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management Registry.
Micheroli R, Kissling S, Bürki K, Möller B, Finckh A, Nissen M, Exer P, Bräm R, Kyburz D, Rubbert-Roth A, Andor M, Baraliakos X, de Hooge M, Distler O, Scherer A, Ciurea A. Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management Registry. Clin Rheumatol 2023; 42:2377-2385.
08.06.2023Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management Registry.
08.06.2023Clin Rheumatol 2023; 42:2377-2385
Micheroli Raphael, Kissling Seraphina, Bürki Kristina, Möller Burkhard, Finckh Axel, Nissen Michael J, Exer Pascale, Bräm René, Kyburz Diego, Rubbert-Roth Andrea, Andor Michael, Baraliakos Xenofon, de Hooge Manouk, Distler Oliver, Scherer Almut, Ciurea Adrian
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis.
Emmi G, Bettiol A, Gelain E, Bajema I, Berti A, Burns S, Cid M, Cohen Tervaert J, Cottin V, Durante E, Holle J, Mahr A, Del Pero M, Marvisi C, Mills J, Moiseev S, Moosig F, Mukhtyar C, Neumann T, Olivotto I, Salvarani C, Seeliger B, Sinico R, Taillé C, Terrier B, Venhoff N, Bertsias G, Guillevin L, Jayne D, Vaglio A. Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol 2023; 19:378-393.
09.05.2023Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis.
09.05.2023Nat Rev Rheumatol 2023; 19:378-393
Emmi Giacomo, Bettiol Alessandra, Gelain Elena, Bajema Ingeborg M, Berti Alvise, Burns Stella, Cid María C, Cohen Tervaert Jan W, Cottin Vincent, Durante Eugenia, Holle Julia U, Mahr Alfred, Del Pero Marcos Martinez, Marvisi Chiara, Mills John, Moiseev Sergey, Moosig Frank, Mukhtyar Chetan, Neumann Thomas, Olivotto Iacopo, Salvarani Carlo, Seeliger Benjamin, Sinico Renato Alberto, Taillé Camille, Terrier Benjamin, Venhoff Nils, Bertsias George, Guillevin Loic, Jayne David R.W., Vaglio Augusto
Management of giant-cell arteritis in Switzerland: an online national survey.
Iudici M, Hemmig A, Stegert M, Courvoisier D, Adler S, Becker M, Berger C, Dan D, Finckh A, Mahr A, Neumann T, Reichenbach S, Ribi C, Seitz L, Villiger P, Wildi L, Daikeler T, Giant Cell Arteritis SCQM Study Group. Management of giant-cell arteritis in Switzerland: an online national survey. Swiss Med Wkly 2023; 153:40051.
03.04.2023Management of giant-cell arteritis in Switzerland: an online national survey.
03.04.2023Swiss Med Wkly 2023; 153:40051
Iudici Michele, Hemmig Andrea Katharina, Stegert Mihaela, Courvoisier Delphine Sophie, Adler Sabine, Becker Mike Oliver, Berger Christoph T, Dan Diana, Finckh Axel, Mahr Alfred, Neumann Thomas, Reichenbach Stephan, Ribi Camillo, Seitz Luca, Villiger Peter M, Wildi Lukas, Daikeler Thomas D, Giant Cell Arteritis SCQM Study Group
Methotrexate in rheumatoid arthritis-another brick in the wall.
Rubbert-Roth A. Methotrexate in rheumatoid arthritis-another brick in the wall. Lancet Rheumatol 2023; 5:e173-e175.
01.04.2023Methotrexate in rheumatoid arthritis-another brick in the wall.
01.04.2023Lancet Rheumatol 2023; 5:e173-e175
Rubbert-Roth Andrea
Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies.
Taylor P, Chen Y, Pope J, Weinblatt M, Mysler E, Rubbert-Roth A, Jia B, Sun L, Liu Y, Holzkämper T, Tanaka Y. Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies. Rheumatol Ther 2023; 10:463-476.
20.01.2023Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies.
20.01.2023Rheumatol Ther 2023; 10:463-476
Taylor Peter C, Chen Yun-Fei, Pope Janet E, Weinblatt Michael, Mysler Eduardo F, Rubbert-Roth Andrea, Jia Bochao, Sun Luna, Liu Yushi, Holzkämper Thorsten, Tanaka Yoshiya
Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.
Amstad A, Papagiannoulis E, Scherer A, Rubbert-Roth A, Finckh A, Mueller R, Dudler J, Möller B, Villiger P, Schulz M, Kyburz D. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy. Rheumatology (Oxford) 2022; 62:89-97.
23.12.2022Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.
23.12.2022Rheumatology (Oxford) 2022; 62:89-97
Amstad Andrea, Papagiannoulis Eleftherios, Scherer Almut, Rubbert-Roth Andrea, Finckh Axel, Mueller Ruediger, Dudler Jean, Möller Burkhard, Villiger Peter M, Schulz Martin, Kyburz Diego
Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA).
Koehm M, Foldenauer A, Rossmanith T, Alten R, Aringer M, Backhaus M, Burmester G, Feist E, Kellner H, Krueger K, Müller-Ladner U, Rubbert-Roth A, Tony H, Wassenberg S, Burkhardt H, Behrens F. Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA). J Clin Med 2022; 11
09.12.2022Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA).
09.12.2022J Clin Med 2022; 11
Koehm Michaela, Foldenauer Ann C, Rossmanith Tanja, Alten Rieke, Aringer Martin, Backhaus Marina, Burmester Gerd R, Feist Eugen, Kellner Herbert, Krueger Klaus, Müller-Ladner Ulf, Rubbert-Roth Andrea, Tony Hans-Peter, Wassenberg Siegfried, Burkhardt Harald, Behrens Frank
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Smolen J, Landewé R, Bergstra S, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards C, Hyrich K, Pope J, de Souza S, Stamm T, Takeuchi T, Verschueren P, Winthrop K, Balsa A, Bathon J, Buch M, Burmester G, Buttgereit F, Cardiel M, Chatzidionysiou K, Codreanu C, Cutolo M, den Broeder A, El Aoufy K, Finckh A, Fonseca J, Gottenberg J, Haavardsholm E, Iagnocco A, Lauper K, Li Z, McInnes I, Mysler E, Nash P, Poór G, Ristic G, Rivellese F, Rubbert-Roth A, Schulze-Koops H, Stoilov N, Strangfeld A, van der Helm-van Mil A, van Duuren E, Vliet Vlieland T, Westhovens R, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2022
10.11.2022EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
10.11.2022Ann Rheum Dis 2022
Smolen Josef S, Landewé Robert B M, Bergstra Sytske Anne, Kerschbaumer Andreas, Sepriano Alexandre, Aletaha Daniel, Caporali Roberto, Edwards Christopher John, Hyrich Kimme L, Pope Janet E, de Souza Savia, Stamm Tanja, Takeuchi Tsutomu, Verschueren Patrick, Winthrop Kevin, Balsa Alejandro, Bathon Joan M, Buch Maya H, Burmester Gerd R, Buttgereit Frank, Cardiel Mario Humberto, Chatzidionysiou Katerina, Codreanu Catalin, Cutolo Maurizio, den Broeder Alfons A, El Aoufy Khadija, Finckh Axel, Fonseca João Eurico, Gottenberg Jacques-Eric, Haavardsholm Espen A, Iagnocco Annamaria, Lauper Kim, Li Zhanguo, McInnes Iain B, Mysler Eduardo F, Nash Peter, Poór Gyula, Ristic Gorica G, Rivellese Felice, Rubbert-Roth Andrea, Schulze-Koops Hendrik, Stoilov Nikolay, Strangfeld Anja, van der Helm-van Mil Annette, van Duuren Elsa, Vliet Vlieland Theodora P M, Westhovens René, van der Heijde Désirée
Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases.
Raptis C, Berger C, Ciurea A, Andrey D, Polysopoulos C, Lescuyer P, Maletic T, Riek M, Scherer A, von Loga I, Safford J, Lauper K, Möller B, Vuilleumier N, Finckh A, Rubbert-Roth A. Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases. Front Immunol 2022; 13:1016927.
13.10.2022Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases.
13.10.2022Front Immunol 2022; 13:1016927
Raptis Catherine E, Berger Christoph T, Ciurea Adrian, Andrey Diego O, Polysopoulos Christos, Lescuyer Pierre, Maletic Tanja, Riek Myriam, Scherer Almut, von Loga Isabell, Safford Judith, Lauper Kim, Möller Burkhard, Vuilleumier Nicolas, Finckh Axel, Rubbert-Roth Andrea
Supplementum 261: Abstracts of the joint annual meeting of the Swiss Society of Rheumatology and the Swiss Society of Physical Medicine and Rehabilitation
Rottländer Y. Supplementum 261: Abstracts of the joint annual meeting of the Swiss Society of Rheumatology and the Swiss Society of Physical Medicine and Rehabilitation. Swiss Medical Weekly 2022; 2022
31.08.2022Supplementum 261: Abstracts of the joint annual meeting of the Swiss Society of Rheumatology and the Swiss Society of Physical Medicine and Rehabilitation
31.08.2022Swiss Medical Weekly 2022; 2022
Rottländer Yella
Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab.
Rubbert-Roth A, Furst D, Fiore S, Praestgaard A, Bykerk V, Bingham C, Charles-Schoeman C, Burmester G. Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab. Arthritis Res Ther 2022; 24:207.
25.08.2022Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab.
25.08.2022Arthritis Res Ther 2022; 24:207
Rubbert-Roth Andrea, Furst Daniel E, Fiore Stefano, Praestgaard Amy, Bykerk Vivian, Bingham Clifton O, Charles-Schoeman Christina, Burmester Gerd R